DUBLIN--(BUSINESS WIRE)--Jan 11, 2019--The "Global Neurodegenerative Diseases Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.
Increase in aging population to drive growth in the market
The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer's and Parkinson's disease.
Availability of highly sensitive diagnostic modalities
The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.
High failure rate of neurodegenerative drugs in clinical trials
There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY INDICATION
Segmentation by indicationComparison by indicationMultiple sclerosis - Market size and forecast 2017-2022Others - Market size and forecast 2017-2022Alzheimer's disease - Market size and forecast 2017-2022Parkinson's disease - Market size and forecast 2017-2022Huntington's disease - Market size and forecast 2017-2022Market opportunity by indication
PART 09: MARKET SEGMENTATION BY DRUG CLASS
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSIS
Vendors coveredVendor classificationMarket positioning of vendorsAllerganBiogenNovartisTeva Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/research/kk6qqx/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005160/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/11/2019 07:14 AM/DISC: 01/11/2019 07:14 AM